Qingdao Vland Biotech INC. Class A

Qingdao Vland Biotech INC. Class A

SSSE:603739
11.60
CNY
+0.10
(+0.87%)
0.39EPS
50.19P/E
3.55BMarket Cap
Apr 26Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4.49
4.66
4.8
4.94
5.02
3.97
4.23
4.69
4.66
4.75
5.27
5.48
5.71
Basic EPS, GAAP
0.33
0.44
0.51
0.53
0.51
0.36
0.48
0.54
0.28
0.32
0.25
0.28
0.28
Free Cash Flow per Basic Share
0.05
0.12
0.79
0.39
0.09
-0.26
-0.17
-1.65
-0.99
-0.25
0.36
0.14
- -
Dividend per Share
0.32
0.17
0.33
0.37
0.38
0.15
0.14
0.15
0.21
0.16
0.22
0.17
0.16
Book Value per Share
2.67
2.98
3.18
3.35
3.51
4.44
4.78
6.36
6.52
6.75
6.87
7.04
7.19
Tangible Book Value per Share
2.21
2.42
2.69
2.83
2.98
4.05
4.17
5.76
5.9
5.87
6.02
6.21
6.31
Basic Weighted Avg Shares
162
161
163
162
162
213
227
246
249
252
251
249
254
Sales/Revenue/Turnover
728
752
781
799
814
847
960
1,151
1,163
1,199
1,321
1,366
1,447
Operating Margin (%)
9.2
10.31
13.9
14.99
14.22
11.06
15.59
15.3
10.78
11.79
11.07
9.81
10
Depreciation Expense
32
34
34
35
36
38
43
52
66
74
111
117
- -
Net Income, GAAP
53
70
83
86
83
78
109
133
70
81
63
70
71
Effective Tax Rate (%)
24.86
20.64
21.49
21.06
16.82
8.42
12.73
12.43
16.42
16.03
25.33
21.21
14.67
Profit Margin (%)
7.31
9.35
10.57
10.71
10.24
9.18
11.35
11.52
6
6.73
4.74
5.11
4.9
Working Capital
167
168
205
213
211
522
469
599
324
36
38
172
286
LT Debt
30
15
- -
3
2
7
- -
99
149
62
14
60
50
Total Equity
466
519
558
593
632
1,032
1,115
1,686
1,734
1,825
1,870
1,911
1,940
Return on Invested Capital (%)
- -
8.82
12.12
14.34
13
10.02
11.17
9.77
4.16
4.35
3.73
4.03
3.97
Return on Capital (%)
- -
11.21
13.14
12.83
11
7.48
8.61
7.53
2.88
2.97
1.96
2.21
2.24
Return on Common Equity (%)
- -
15.31
16.5
16.14
14.97
10.15
10.92
10.05
4.3
4.81
3.64
3.97
3.99

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
646
619
547
LT Borrowings
50
50
50
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
253
253
253
Market Capitalization
3,717
2,917
3,553

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,238
1,238
1,217
Cash, Cash Equivalents & STI
497
472
438
Accounts Receivable, Net
387
410
440
Inventories
231
243
226
Total Current Liabilities
1,041
1,002
931
Payables & Accruals
- -
- -
- -
ST Debt
646
619
547
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.56%
12.78%
2.18%
Free Cash Flow
44.94%
103.61%
-62.58%
Net Income, GAAP
3.09%
-4.21%
11.45%
Sales/Revenue/Turnover
6.31%
7.52%
3.43%
Total Cash Common Dividend
10.92%
9.57%
-22.13%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
287
322
336
375
1,321
2025
310
342
- -
350
1,366
2026
345
365
387
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
0.07
0.05
0.09
0.25
2025
0.04
0.07
- -
0.03
0.28
2026
0.07
0.08
0.1
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.12
0.02
0.06
0.22
2025
0.02
0.12
- -
0.02
0.17
2026
0.01
0.11
0.01
- -
- -

Company Description

CEO
Gang Chen
Full Time Employees
1,522
Sector
Health technology
Industry
Biotechnology
Address
No. 596-1, Jiushui East Road Qingdao SD China 266100
IPO Date
Jan 16, 2019
Business
Qingdao Vland Biotech Inc. (603739.SS) engages in the research, development, production and sale of enzyme preparations, microecological preparations, animal health products and marine aquaculture solutions principally in China and internationally. The company offers a broad portfolio of products including feed enzymes, industrial enzymes and food enzymes; probiotics such as aquaculture premixes, health products, animal probiotics and plant probiotics; animal vaccines and biological products encompassing live and inactivated poultry and swine vaccines as well as egg yolk antibodies; poultry drugs comprising antiparasitic, antiviral and nutritional drugs together with disinfectants; and traditional Chinese veterinary medicines for livestock, scale, avian breeding and laying hens. It operates across industries such as agriculture, animal husbandry, textile, pulp and paper, health care, laundry, biofuel, household cleaning, detergents, food, animal feed, environmental protection and washing. Founded in 2005 and headquartered at Vland Innovation Park, No. 596-1 Jiushui East Road, Laoshan District, Qingdao, Shandong, China, the company maintains 33 subsidiary companies, nine production bases and nine technology centers with over 1,500 employees worldwide. Qingdao Vland Biotech Inc. listed on the Shanghai Stock Exchange A-shares main board in 2019. Recent developments include the January 2024 operational launch of Evonik Vland Biotech (Shandong) Co., Ltd., a joint venture with Evonik based in Qingdao and utilizing production facilities in Huimin to expand market presence with probiotics and solutions for livestock gut health, complemented by Evonik's distribution outside Greater China. The company established Vland Biotechnology Ho Chi Minh Company Limited in Vietnam in 2018 and the Vland-ADM Joint Enzyme R&D Center in California, US, in 2017, while forming an ADM joint venture in 2021 to address growing Chinese demand for human probiotics; in 2022, it created ADM-Vland Biotech (Shandong) Co., Ltd.